Balaji Amines Ltd
Balaji Amines Ltd
ChemicalsKey Fundamentals
MicrocapSpecialty ChemicalsChemicalsInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Balaji Amines Ltd insights
48 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 20.4%
- Company's working capital requirements have reduced from 101 days to 68.8 days
Weaknesses
3- Stock is trading at 3.48 times its book value
- The company has delivered a poor sales growth of 1.64% over past five years.
- Company has a low return on equity of 9.92% over last 3 years.
Growth Rate
AI Analysis — Bull vs Bear
Balaji Amines Ltd is a nearly debt-free specialty chemicals company trading at a market cap of ₹7,126 Cr and a PE of 42.2x. After a prolonged earnings downcycle (FY22-FY25), the company is showing early signs of recovery with Q4 FY26 net profit up 57.6% YoY and EBITDA margins expanding to 25%, though 5-year compounded profit growth remains negative at -7% and ROE has fallen to single digits.
- Company is virtually debt-free, providing financial flexibility for its ongoing ₹1,100 Cr capex cycle without balance sheet stress
- Q4 FY26 net profit surged 57.6% YoY to ₹63.2 Cr with EBITDA margin expanding 695 bps to 25%, signaling a meaningful operational recovery
- Management has guided 10-15% volume growth for FY27 with target EBITDA margins of 22-23%, supported by new DME, NMM, and Acetonitrile plant ramp-ups
- Working capital efficiency has improved significantly from 101 days to 68.8 days, freeing up cash for operations
- FY26 full-year revenue of ₹1,454 Cr and net profit of ₹169 Cr show a recovery trend, with EPS rising from ₹48.62 to ₹51.60
- 10-year stock CAGR of 23% and 10-year compounded profit growth of 11% demonstrate a long-term value creation track record
- Consistent dividend payout of ~20-22% maintained even through the downcycle, with current yield at 0.5%
- PE ratio of 42.2x is expensive relative to a last-year ROE of just 9% and 3-year average ROE of only 10%
- 5-year compounded profit growth is negative at -7% and 3-year compounded sales growth is -15%, reflecting a deep and prolonged earnings downcycle
- Stock trades at 3.61x book value despite delivering sub-10% ROE in the most recent year, suggesting valuation is pricing in a recovery that is not yet fully visible
- 5-year compounded sales growth of just 1.64% indicates persistent demand and pricing challenges in the amines/specialty chemicals space
- FY26 full-year revenue of ₹1,454 Cr is still well below the FY23 peak of ₹2,355 Cr, a 38% decline from cyclical highs
- 3-year stock CAGR of -2% and 5-year stock CAGR of -4% show the market has not rewarded shareholders over medium-term horizons
- EBITDA margin of 18.26% for full-year FY26 remains below the FY22-FY23 levels of 25-27%, indicating incomplete margin normalization
- Specialty chemicals sector faces ongoing pricing pressure from Chinese competition, which contributed to the revenue decline from FY23 peaks
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Strong FY26 earnings, ₹11 dividend Jun 16
FY26 consolidated revenue at ₹1,454 crore with PAT of ₹169 crore. Board recommended dividend of ₹11 per share; 38th AGM set for July 10, 2026.
- 10-15% volume growth guided FY27 Jun 16
Co-Chairman Anup Pratap Reddy projects 10-15% volume growth for FY27 with EBITDA margin target of 22-23%. Medium-term aim of 20-30% volume growth supported by DME, NMM, ACN, and BSCL expansion.
- July 3 record date for dividend Jun 8
Balaji Amines set July 3, 2026 as the record date for its FY26 final dividend ahead of the July 10 AGM.
- BRSR filed, 34% renewable energy Jun 16
FY26 BRSR reports 34% renewable energy usage and 100% zero liquid discharge compliance across all operations.
TL;DR: Balaji Amines delivered solid FY26 results with ₹1,454 crore revenue and ₹169 crore PAT, and management is guiding 10-15% volume growth in FY27 with healthy EBITDA margins of 22-23%. No material headwinds surfaced in recent news flow. The sustainability disclosures and capacity expansion across multiple product lines suggest an improving operational trajectory heading into FY27.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 464 | 381 | 383 | 414 | 385 | 347 | 313 | 353 | 358 | 341 | 331 | 395 | 456 |
| Expenses | 366 | 327 | 309 | 316 | 319 | 286 | 267 | 293 | 304 | 281 | 275 | 301 | 340 |
| Operating Profit | 98 | 54 | 74 | 98 | 66 | 61 | 46 | 60 | 55 | 60 | 57 | 94 | 116 |
| OPM % | 21% | 14% | 19% | 24% | 17% | 17% | 15% | 17% | 15% | 18% | 17% | 24% | 25% |
| Other Income | 6 | 7 | 8 | 9 | 8 | 9 | 8 | 8 | 9 | 7 | 5 | 8 | 6 |
| Interest | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 13 | 14 | 14 | 14 | 14 | 14 |
| PBT | 90 | 48 | 70 | 93 | 62 | 57 | 41 | 54 | 49 | 52 | 46 | 86 | 106 |
| Tax % | 25% | 24% | 21% | 22% | 26% | 27% | 24% | 25% | 25% | 28% | 33% | 25% | 26% |
| Net Profit | 68 | 36 | 56 | 72 | 46 | 41 | 31 | 40 | 37 | 37 | 31 | 65 | 78 |
| EPS in Rs | 16.27 | 10.71 | 15.24 | 21 | 13.36 | 12.65 | 10.24 | 12.36 | 11.73 | 10.67 | 9.7 | 19.51 | 23.13 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 616 | 640 | 668 | 858 | 940 | 935 | 1,308 | 2,314 | 2,346 | 1,631 | 1,389 | 1,419 | 1,523 |
| Expenses | 515 | 514 | 519 | 676 | 747 | 754 | 935 | 1,691 | 1,736 | 1,308 | 1,157 | 1,154 | 1,196 |
| Operating Profit | 102 | 127 | 149 | 182 | 193 | 181 | 373 | 623 | 609 | 324 | 232 | 265 | 327 |
| OPM % | 17% | 20% | 22% | 21% | 21% | 19% | 29% | 27% | 26% | 20% | 17% | 19% | 21% |
| Other Income | 4 | 3 | 9 | 12 | 4 | 5 | 6 | 15 | 15 | 30 | 33 | 29 | 25 |
| Interest | 35 | 22 | 13 | 9 | 13 | 23 | 18 | 17 | 12 | 6 | 4 | 5 | 6 |
| Depreciation | 20 | 19 | 20 | 19 | 20 | 32 | 34 | 42 | 46 | 45 | 48 | 56 | 56 |
| PBT | 51 | 88 | 126 | 166 | 165 | 131 | 327 | 578 | 567 | 302 | 213 | 232 | 290 |
| Tax % | 35% | 34% | 34% | 32% | 29% | 26% | 25% | 28% | 28% | 23% | 26% | 27% | — |
| Net Profit | 33 | 58 | 82 | 113 | 117 | 97 | 243 | 418 | 406 | 232 | 159 | 169 | 211 |
| EPS in Rs | 10.25 | 17.78 | 25.42 | 34.93 | 36.27 | 32.34 | 73.51 | 114 | 100 | 63.22 | 48.62 | 51.6 | 63.01 |
| Div. Payout % | 12% | 11% | 9% | 7% | 8% | 10% | 5% | 5% | 10% | 17% | 23% | 21% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 221 | 274 | 356 | 461 | 568 | 652 | 888 | 1,243 | 1,548 | 1,715 | 1,839 | 1,970 |
| Borrowings | 256 | 173 | 105 | 152 | 227 | 260 | 127 | 101 | 58 | 20 | 11 | 133 |
| Other Liabilities | 139 | 152 | 168 | 229 | 244 | 195 | 289 | 395 | 351 | 405 | 396 | 633 |
| Total Liabilities | 623 | 605 | 635 | 848 | 1,046 | 1,113 | 1,310 | 1,745 | 1,963 | 2,146 | 2,252 | 2,743 |
| Fixed Assets | 341 | 341 | 325 | 316 | 320 | 573 | 543 | 681 | 780 | 896 | 1,003 | 1,043 |
| CWIP | 3 | 16 | 25 | 123 | 269 | 46 | 173 | 141 | 113 | 205 | 238 | 512 |
| Investments | 0 | 0 | 0 | 0 | 0 | 48 | 0 | 0 | 73 | 0 | 0 | 0 |
| Other Assets | 278 | 248 | 284 | 409 | 457 | 446 | 594 | 923 | 996 | 1,046 | 1,011 | 1,188 |
| Total Assets | 623 | 605 | 635 | 848 | 1,046 | 1,113 | 1,310 | 1,745 | 1,963 | 2,146 | 2,252 | 2,743 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 56 | 85 | 60 | 140 | 94 | 144 | 110 | 220 | 354 | 334 | 255 | 184 |
| Investing | -4 | -29 | -10 | -135 | -119 | -130 | -62 | -147 | -210 | -274 | -139 | -344 |
| Financing | -55 | -54 | -55 | 16 | 21 | -26 | -37 | -57 | -81 | -75 | -49 | 85 |
| Net Cash Flow | -3 | 2 | -5 | 21 | -4 | -12 | 11 | 16 | 63 | -15 | 68 | -75 |
| Free Cash Flow | 48 | 53 | 47 | 32 | -75 | 83 | -21 | 72 | 234 | 82 | 69 | -186 |
| CFO/OP | 65 | 77 | 58 | 101 | 74 | 108 | 40 | 56 | 81 | 123 | 128 | 82 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 71 | 68 | 73 | 65 | 81 | 85 | 93 | 59 | 71 | 72 | 89 |
| Inventory Days | 114 | 80 | 106 | 70 | 116 | 77 | 64 | 66 | 89 | 116 | 128 | 113 |
| Days Payable | 48 | 58 | 55 | 56 | 60 | 42 | 44 | 54 | 18 | 31 | 32 | 39 |
| Cash Conversion Cycle | 136 | 93 | 119 | 87 | 120 | 116 | 104 | 105 | 129 | 156 | 168 | 163 |
| Working Capital Days | 7 | 12 | 42 | 31 | 47 | 55 | 88 | 88 | 89 | 114 | 120 | 69 |
| ROCE % | 18% | 23% | 30% | 32% | 24% | 18% | 35% | 49% | 36% | 17% | 11% | 11% |
Documents
Frequently Asked Questions about Balaji Amines Ltd
What does Balaji Amines Ltd do?
Where is Balaji Amines Ltd (BALAMINES) listed?
Which sector does Balaji Amines Ltd belong to?
What is the market capitalisation of Balaji Amines Ltd?
What is the PE ratio of Balaji Amines Ltd?
What is the 52-week high and low of Balaji Amines Ltd?
Does Balaji Amines Ltd pay dividends?
What is the Return on Equity (ROE) of Balaji Amines Ltd?
How can I research Balaji Amines Ltd on Tapetide?
Company Information
Incorporate in 1989, Balaji Amines Ltd is engaged in manufacturing of specialty chemicals, aliphatic amines, and derivatives, along with ownership of a five-star hotel in Solapur, Maharashtra.[1]